Actemra® Injection (Tocilizumab)

**Warnings**

1. **Infections**
   Actemra has been associated with serious and sometimes fatal infections including sepsis and pneumonia. Actemra exerts its therapeutic effects by suppressing the action of IL-6, a cytokine that induces acute phase reactions (fever, increase in C-reactive protein, etc.). Treatment with Actemra suppresses these reactions and accordingly suppresses signs and symptoms associated with infection, which may delay the detection of infections. As a result, it may potentially make the infection more serious. Therefore, patients should be monitored closely and interviewed during treatment with Actemra. Changes in white blood cell and neutrophil counts should be carefully evaluated even when symptoms are mild and no acute phase reaction is observed. If infection is suspected, a chest X-ray, CT scan, etc., should be performed and appropriate measures should be taken.

2. Actemra treatment should be started only after patients are thoroughly informed that adverse drug reactions such as serious infections may occur and that Actemra may not completely resolve their disease, and only when the potential benefit of treatment is judged to outweigh the potential risk.

3. Before treatment with Actemra is given to patients with rheumatoid arthritis (RA) and polyarticular-course juvenile idiopathic arthritis (pJIA), use of one or more disease-modifying anti-rheumatic drugs (DMARDs) should be thoroughly considered. Actemra should be used by a physician with sufficient knowledge of Actemra and experience with the treatment of RA and/or pJIA.

4. For patients with systemic juvenile idiopathic arthritis (sJIA), Actemra should be used by a physician with sufficient knowledge of Actemra and experience with the treatment of sJIA.

---

**1. Description**

1.1 Therapeutic/Pharmacologic Class of Drug

Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) IgG1 subclass.

ATC Code: L04AC07.

1.2 Type of Dosage Form

Intravenous (IV) formulation: Concentrate solution for infusion

1.3 Route of Administration

Intravenous (IV) infusion

1.4 Sterile/Radioactive Statement

Sterile
1.5 Qualitative and Quantitative Composition

Active ingredient: tocilizumab
Excipients: Sucrose, Polysorbate 80, Disodium phosphate dodecahydrate, Sodium dihydrogen phosphate dihydrate and Water for injections

Tocilizumab solution for intravenous (IV) infusion is a clear to opalescent, colourless to pale yellow liquid, supplied in preservative-free, non-pyrogenic single-use vials, supplied in 10 mL and 20 mL vials containing 4 mL, 10 mL or 20 mL of Tocilizumab (20 mg/mL).

2. Clinical Particulars

2.1 Therapeutic Indications

Rheumatoid Arthritis (RA)
Tocilizumab is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients. Tocilizumab can be used alone or in combination with methotrexate (MTX) and/or other disease-modifying antirheumatic drugs (DMARDs). Tocilizumab has been shown to inhibit progression of joint damage as measured by X-ray and to improve physical function.

Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Tocilizumab is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Tocilizumab can be given alone or in combination with MTX.

Systemic Juvenile Idiopathic Arthritis (sJIA)

Intravenous Formulation
Tocilizumab is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

2.2 Dosage and Administration

General
Substitution by any other biological medicinal product requires the consent of the prescribing physician.
For adult patients with RA, tocilizumab may be administered as an IV infusion.
For patients with pJIA, tocilizumab is administered as an IV infusion.
For patients with sJIA tocilizumab is administered as an IV infusion.

Intravenous Administration
Tocilizumab IV formulation should be diluted by a healthcare professional with sterile 0.9% w/v sodium chloride solution using aseptic technique (see section 4.2 Special Instructions for Use, Handling and Disposal). The recommended duration of IV infusion is 1 hour.

Rheumatoid Arthritis
Intravenous Dosing regimen:
The recommended dose of Tocilizumab for adult patients is 8 mg/kg body weight, given once every four weeks as an IV infusion. Tocilizumab can be used alone or in combination with MTX and/or other DMARDs.
For individuals whose body weight is more than 100 kilograms (kg), doses exceeding 800mg per infusion are not recommended (see Section 3.2 Pharmacokinetic Properties)

Dose Modification Recommendations for RA: (see section 2.4.1 Warnings and Precautions, General)

Liver enzyme abnormalities

| Laboratory Value | Action |
Dose modify concomitant DMARDs (RA) if appropriate. For patients on intravenous tocilizumab (RA only) with persistent increases in this range, reduce tocilizumab dose to 4 mg/kg or interrupt tocilizumab until alanine aminotransferase (ALT) or aspartate aminotransferase (AST) have normalized. Restart with 4 mg/kg or 8 mg/kg, as clinically appropriate.

> 3 to 5x ULN
Interrupt tocilizumab dosing until < 3x ULN and follow recommendations above for >1 to 3x ULN. For persistent increases > 3x ULN (confirmed by repeat testing, see section 2.4.4), discontinue tocilizumab.

> 5x ULN
Discontinue tocilizumab.

### Low absolute neutrophil count (ANC)

<table>
<thead>
<tr>
<th>Laboratory Value (cells x $10^9$/L)</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANC &gt; 1</td>
<td>Maintain dose</td>
</tr>
<tr>
<td>ANC 0.5 to 1</td>
<td>Interrupt tocilizumab dosing. For patients on intravenous tocilizumab (RA only), when ANC &gt; 1 x $10^9$/L resume tocilizumab at 4 mg/kg and increase to 8 mg/kg as clinically appropriate</td>
</tr>
<tr>
<td>ANC &lt; 0.5</td>
<td>Discontinue tocilizumab</td>
</tr>
</tbody>
</table>

### Low platelet count

<table>
<thead>
<tr>
<th>Laboratory Value (cells x $10^3$/mL)</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 to 100</td>
<td>Interrupt tocilizumab dosing. For patients on intravenous tocilizumab (RA only), when platelet count is &gt; 100 x $10^3$/mL resume tocilizumab at 4 mg/kg and increase to 8 mg/kg as clinically appropriate</td>
</tr>
<tr>
<td>&lt; 50</td>
<td>Discontinue tocilizumab</td>
</tr>
</tbody>
</table>

**Polyarticular Juvenile Idiopathic Arthritis (pJIA)**
A change in dose should only be based on a consistent change in the patient’s body weight over time. Tocilizumab can be used alone or in combination with MTX.

**Intravenous Dosing Regimen:**
The recommended dose of IV tocilizumab for patients with pJIA is:
- 10 mg/kg for patients below 30 kg,
- 8 mg/kg for patients $\geq$ 30 kg,
  - given once every four weeks as an IV infusion

**Systemic Juvenile Idiopathic Arthritis (sJIA)**
A change in dose should only be based on a consistent change in the patient’s body weight over time. Tocilizumab can be used alone or in combination with MTX.

**Intravenous Dosing Regimen:**
The recommended dose of IV tocilizumab for patients with sJIA is:
12 mg/kg for patients below 30 kg,
8 mg/kg for patients ≥ 30 kg,
given once every two weeks as an IV infusion

**Dose Modification Recommendations for pJIA and sJIA:**
Dose reduction of tocilizumab has not been studied in the pJIA or sJIA population. Dose interruptions of tocilizumab for laboratory abnormalities are recommended in patients with pJIA or sJIA and are similar to what is outlined above for patients with RA (also see section 2.4.1 Warnings and Precautions, General). If appropriate, concomitant methotrexate and/or other medications should be dose modified or stopped and tocilizumab dosing interrupted until the clinical situation has been evaluated. In pJIA or sJIA, the decision to discontinue tocilizumab for a laboratory abnormality should be based upon the medical assessment of the individual patient.

**2.2.1 Special Dosage Instructions**

**Pediatric use:**
The safety and efficacy of tocilizumab in patients aged less than 2 years in pJIA has not been established. The safety and efficacy in patients aged less than 2 years with IV TCZ in sJIA or less than 1 year with SC TCZ in sJIA have not been established.

**Geriatric use:** No dose adjustment is required in elderly patients aged >65 years of age.

**Renal impairment:** No dose adjustment is required in patients with mild or moderate renal impairment (see section 3.2.5 Pharmacokinetics in Special Populations). Tocilizumab has not been studied in patients with severe renal impairment.

**Hepatic impairment:** The safety and efficacy of tocilizumab has not been studied in patients with hepatic impairment (see section 2.4.1 Warnings and Precautions, General).

**2.3 Contraindications**
Actemra is contraindicated in patients with Known hypersensitivity to tocilizumab or to any of the excipients.

**2.4 Warnings and Precautions**

**2.4.1 General**
In order to improve the traceability of biological medicinal products, the trade name and batch number of the administered product should be clearly recorded (or stated) in the patient file.

**All indications:**

**Infections**
Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents including tocilizumab (see section 2.6, Undesirable Effects). Tocilizumab treatment should not be initiated in patients with active infections. Administration of tocilizumab should be interrupted if a patient develops a serious infection until the infection is controlled. Healthcare professionals should exercise caution when considering the use of tocilizumab in patients with a history of recurring infection or with underlying conditions (e.g. diverticulitis, diabetes) which may predispose patients to infections.

Vigilance for the timely detection of serious infection is recommended for patients receiving immunosuppressive agents, such as tocilizumab, as signs and symptoms of acute inflammation may be lessened, due to suppression of the acute phase reactants. Patients (which include younger children who may be less able to communicate their symptoms) and parents/guardians of minors should be instructed to contact their healthcare professional immediately when any symptoms suggesting infection appear, in order to assure rapid evaluation and appropriate treatment.

**Complications of diverticulitis**
Events of diverticular perforation as complications of diverticulitis have been reported in patients treated with tocilizumab. Tocilizumab should be used with caution in patients with previous history of intestinal ulceration or
diverticulitis. Patients presenting with symptoms potentially indicative of complicated diverticulitis, such as abdominal pain, should be evaluated promptly for early identification of gastrointestinal perforation.

**Tuberculosis**

As recommended for other biologic therapies in all patients should be screened for latent tuberculosis infection prior to starting tocilizumab therapy. Patients with latent tuberculosis should be treated with standard antimycobacterial therapy before initiating tocilizumab.

**Vaccinations**

Live and live attenuated vaccines should not be given concurrently with tocilizumab as clinical safety has not been established.

No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving tocilizumab.

In a randomized open-label study, adult RA patients treated with tocilizumab and MTX were able to mount an effective response to both the 23-valent pneumococcal polysaccharide and tetanus toxoid vaccines which was comparable to the response seen in patients on MTX only.

It is recommended that all patients, particularly pediatric or elderly patients, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating tocilizumab therapy. The interval between live vaccinations and initiation of tocilizumab therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents.

**Hypersensitivity Reactions**

Serious hypersensitivity reactions, including anaphylaxis have been reported in association with tocilizumab (see section 2.6.1 Undesirable Effects, Clinical Trials). In the post marketing setting, events of serious hypersensitivity and anaphylaxis have occurred in patients treated with a range of doses of tocilizumab, with or without concomitant therapies, premedication, and/or a previous hypersensitivity reaction. In the post marketing setting, cases with a fatal outcome have been reported with intravenous tocilizumab. These events have occurred as early as the first infusion of tocilizumab (see sections 2.3 Contraindications, 2.6.2 Post Marketing).

Appropriate treatment should be available for immediate use in the event of an anaphylactic reaction during infusion with tocilizumab. If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of tocilizumab should be stopped immediately and tocilizumab should be permanently discontinued (see section 2.2 Dosage and Administration).

**Active Hepatic Disease and Hepatic Impairment**

Treatment with tocilizumab particularly when administered concomitantly with methotrexate, may be associated with elevations in hepatic transaminases therefore caution should be exercised when considering treatment of patients with active hepatic disease or hepatic impairment (see section 2.2.1 Special Dosage Instructions, 2.6.1 Undesirable Effects, Clinical Trials).

**Hepatotoxicity**

Mild and moderate elevations of hepatic transaminases have been observed with tocilizumab treatment (see section 2.6.1 Undesirable Effects, Clinical Trials). Increased frequency of these elevations was observed when drugs, which are known to cause hepatotoxicity (e.g. methotrexate (MTX)), were used in combination with tocilizumab.

Serious drug-induced liver injury, including acute liver failure, hepatitis and jaundice, have been observed with tocilizumab (see section 2.6.2 Undesirable Effects, Post Marketing Experience). Serious hepatic injury occurred between 2 weeks to more than 5 years after initiation of tocilizumab. Cases of liver failure resulting in liver transplantation have been reported.

Caution should be exercised when considering initiation of tocilizumab treatment in patients with elevated transaminases ALT or AST above 1.5x ULN. In patients with elevated ALT or AST above 5x ULN treatment is not
recommended.
In RA, pJIA and sJIA, ALT/AST should be monitored every 4 to 8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter. For recommended dose modifications, including tocilizumab discontinuation, based on transaminases levels, see section 2.2 Dosage and Administration.

**Viral reactivation**
Viral reactivation (e.g. hepatitis B virus) has been reported with biologic therapies for rheumatoid arthritis. In clinical studies with tocilizumab, patients who screened positive for hepatitis were excluded.

**Demyelinating disorders**
Physicians should be vigilant for symptoms potentially indicative of new onset central demyelinating disorders. The potential for central demyelination with tocilizumab is currently unknown.

**Neutropenia**
Treatment with tocilizumab was associated with a higher incidence of neutropenia. Treatment-related neutropenia was not associated with serious infection in clinical trials (see section 2.6.1 Undesirable Effects, Clinical Trials).
Caution should be exercised when considering initiation of tocilizumab treatment in patients with a low neutrophil count i.e. absolute neutrophil count (ANC) below 2 x 10⁹/L. In patients with an absolute neutrophil count below 0.5 x 10⁹/L treatment is not recommended.
In RA, the neutrophil count should be monitored 4 to 8 weeks after start of therapy and thereafter according to good clinical practice. For recommended dose modifications based on ANC results, see section 2.2 Dosage and Administration. In pJIA and sJIA, the neutrophil count should be monitored at the time of the second administration and thereafter according to good clinical practice (see section 2.2 Dosage and Administration, Dose modifications).

**Thrombocytopenia**
Treatment with tocilizumab was associated with a reduction in platelet counts. Treatment-related reduction in platelets was not associated with serious bleeding events in clinical trials (see section 2.6.1 Undesirable Effects, Clinical Trials).
Caution should be exercised when considering initiation of tocilizumab treatment in patients with a platelet count below 100 x 10³/µL. In patients with a platelet count below 50 x 10³/µL treatment is not recommended.
In RA, platelets should be monitored 4 to 8 weeks after start of therapy and thereafter according to good clinical practice. For recommended dose modifications based on platelet counts, see section 2.2 Dosage and Administration. In pJIA and sJIA, platelets should be monitored at the time of the second administration and thereafter according to good clinical practice (see section 2.2 Dosage and Administration, Dose modifications).

**Lipids parameters**
Elevations of lipid parameters such as total alanine aminotransferase, triglycerides and/or low density lipoprotein (LDL) cholesterol have been observed (see section 2.6.1 Undesirable Effects, Clinical Trials).
In patients treated with tocilizumab, assessment of lipid parameters should be performed 4 to 8 weeks following initiation of tocilizumab therapy. Patients should be managed according to local clinical guidelines for management of hyperlipidaemia.

**Systemic Juvenile Idiopathic Arthritis:**

**Macrophage activation syndrome (MAS)**
MAS is a serious life-threatening disorder that may develop in patients with sJIA. In clinical trials, tocilizumab has not been studied in patients during an episode of active MAS.

**2.4.2 Drug Abuse and Dependence**
No studies on the effects on the potential for tocilizumab to cause dependence have been performed. However, there is no evidence from the available data that tocilizumab treatment results in dependence.

**2.4.3 Ability to Drive and Use Machines**
No studies on the effects on the ability to drive and use machine have been performed. However, there is no evidence
from the available data that tocilizumab treatment affects the ability to drive and use machines.

2.5 Use in Special Populations

2.5.1 Pregnancy
There are no adequate data from the use of tocilizumab in pregnant women. A study in monkeys did not indicate any
dysmorphogenic potential but has yielded a higher number of spontaneous abortion/embryo-foetal death at a high dose
(see section 3.3.5 Pre-clinical Safety, Other). The relevance of these data for humans is unknown.
Tocilizumab should not be used during pregnancy unless clearly indicated by medical need.

2.5.2 Labour and Delivery
No text

2.5.3 Nursing Mothers
It is unknown whether tocilizumab is excreted in human breast milk. Although endogenous immunoglobulins of the IgG
isotope are secreted into human milk, a systemic absorption of tocilizumab via breast feeding is unlikely due to the rapid
proteolytic degradation of such proteins in the digestive system. A decision on whether to continue/discontinue breast-
feeding or to continue/discontinue therapy with tocilizumab should be made taking into account the benefit of breast-
feeding to the child and the benefit of tocilizumab therapy to the woman.

2.5.4 Paediatric Use
(See section 2.2.1 Special Dosage Instructions).

2.5.5 Geriatric Use
(See section 2.2.1 Special Dosage Instructions, section 3.2.5 Pharmacokinetics in Special Populations).

2.5.6 Renal Impairment
(See section 2.2.1 Special Dosage Instructions, section 3.2.5 Pharmacokinetics in Special Populations).

2.5.7 Hepatic Impairment
(See section 2.2.1 Special Dosage Instructions, section 3.2.5 Pharmacokinetics in Special Populations).

2.6 Undesirable Effects

2.6.1 Clinical Trials
The safety profile in this section comes from 4510 patients exposed to tocilizumab in clinical trials; the majority of these
patients were participating in RA studies (n=4009) while the remaining experience comes from pJIA (n=240), sjIA
(n=112). The safety profile of tocilizumab across these indications remains similar and undifferentiated.
Adverse Drug Reactions (ADRs) from clinical trials (Table1) is listed by MedDRA system organ class according to clinical
importance to the patient. The corresponding frequency category for each ADR is based on the following convention:
very common (≥1/10), common (≥1/100 to < 1/10) or uncommon (≥1/1000 to < 1/100).

Table 1: Summary of ADRs occurring in patients treated with Tocilizumab

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Very Common</th>
<th>Common</th>
<th>Uncommon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Upper respiratory tract infections</td>
<td>Cellulitis, Oral herpes simplex, Herpes zoster</td>
<td>Diverticulitis</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Abdominal pain, Mouth ulceration, Gastritis</td>
<td>Stomatitis, Gastric ulcer</td>
<td></td>
</tr>
</tbody>
</table>
Skin and subcutaneous tissue disorders

- Rash, Pruritus, Urticaria

Nervous system disorders

- Headache, Dizziness

Investigations

- Hepatic transaminases increased, Weight increased,
  Total bilirubin increased

Vascular disorders

- Hypertension

Blood and lymphatic system disorders

- Leukopenia, Neutropenia

Metabolism and nutrition disorders

- Hypercholesterolaemia
  Hypertriglyceridaemia

General disorders and administration site conditions

- Injection site reaction
  Peripheral oedema
  Hypersensitivity reactions, Injection site reaction

Respiratory, thoracic and mediastinal disorders

- Cough, Dyspnoea

Eye disorders

- Conjunctivitis

Renal disorders

- Nephrolithiasis

Endocrine disorders

- Hypothyroidism

Description of selected adverse drug reactions from clinical trials:

**Rheumatoid Arthritis**

**Patients Treated with Intravenous Tocilizumab:**

The safety of tocilizumab has been studied in 5 Phase III, double-blind controlled trials and their extension periods. The all control population includes all patients from the double-blind phases of each core study from randomization until either the first change in the treatment regimen, or two years is reached. The control period in 4 of the studies was 6 months and in 1 study was up to 2 years. In the double-blind controlled studies, 774 patients received tocilizumab 4 mg/kg in combination with MTX, 1870 patients received Tocilizumab 8 mg/kg in combination with MTX/other DMARDs, and 288 patients received tocilizumab 8 mg/kg monotherapy.

The all exposure population includes all patients who received at least one dose of tocilizumab either in the double-blind control period or open label extension phase in studies. Of the 4009 patients in this population, 3577 received treatment for at least 6 months, 3296 for at least one year; 2806 received treatment for at least 2 years and 1222 for 3 years.

**Infections**
In the 6-month controlled trials, the rate of all infections reported with tocilizumab 8 mg/kg plus DMARD treatment was 127 events per 100 patient (pt) years compared to 112 events per 100 pt years in the placebo + DMARD group. In the all exposure population, the overall rate of infections with tocilizumab was 108 events per 100 pt years exposure.

In 6-month controlled clinical trials, the rate of serious infections (bacterial, viral and fungal) with tocilizumab 8 mg/kg + DMARD was 5.3 events per 100 pt years exposure compared to 3.9 events per 100 pt years exposure in the placebo+ DMARD group. In the monotherapy study the rate of serious infections was 3.6 events per 100 pt years of exposure in the tocilizumab group and 1.5 events per 100 pt years of exposure in the MTX group.

In the all exposure population, the overall rate of serious infections was 4.7 events per 100 pt years. Reported serious infections, some with fatal outcome, included pneumonia, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, bacterial arthritis. Cases of opportunistic infections have also been reported.

**Gastrointestinal Perforation**

During the 6 month controlled clinical trials, the overall rate of gastrointestinal perforation was 0.26 events per 100 pt years with tocilizumab therapy. In the all exposure population the overall rate of gastrointestinal perforation was 0.28 events per 100 pt years. Reports of gastrointestinal perforation on tocilizumab were primarily reported as complications of diverticulitis including generalized purulent peritonitis, lower GI perforation, fistula and abscess.

**Infusion reactions**

In the 6-month controlled trials adverse events associated with infusion (selected events occurring during or within 24 hours of infusion) were reported by 6.9% of patients in the tocilizumab 8 mg/kg + DMARD and 5.1% of patients in the placebo + DMARD group. Events reported during the infusion were primarily episodes of hypertension; events reported within 24 hours of finishing an infusion were headache and skin reactions (rash, urticaria). These events were not treatment limiting.

The rate of anaphylaxis (occurring in a total of 6/3778 patients) was several-fold higher in the 4 mg/kg arm in comparison to the 8 mg/kg dose. Clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation, were reported in a total of 13 out of 3778 patients (0.3%) treated with tocilizumab during the controlled and open label clinical trials. These reactions were generally observed during the second to fifth infusions of tocilizumab (see section 2.4.1 Warnings and Precautions, General).

**Immunogenicity**

A total of 2876 patients have been tested for anti-tocilizumab antibodies in the 6-month controlled clinical trials. Forty six patients (1.6%) developed positive anti-tocilizumab antibodies of whom 5 had an associated medically significant hypersensitivity reaction leading to withdrawal. Thirty patients (1.1%) developed neutralising antibodies.

**Early Rheumatoid Arthritis**

Study VI (WA19926) evaluated 1162 patients with early, moderate to severe RA who were naïve to treatment with both MTX and a biologic agent. The overall safety profile observed in the tocilizumab treatment groups was consistent with the known safety profile of tocilizumab (see Table 1) (see section 3.2 Clinical/Efficacy Studies).

**Monotherapy: tocilizumab versus adalimumab**

In a 24 week double-blinded, parallel study (monotherapy with tocilizumab 8 mg/kg IV q4w (N=162) compared to adalimumab 40 mg SC q2w (N=162)), the overall clinical adverse event profile was similar between tocilizumab and adalimumab. The proportion of patients with serious adverse events was balanced between the treatment groups (tocilizumab 11.7% vs. adalimumab 9.9%) with the most common event being infections (3.1% each). Both study treatments induced the same pattern of changes in laboratory safety parameters (decreases in neutrophil and platelet counts, increases in ALT, AST and lipids), however, the magnitude of change and the frequency of marked abnormalities was higher with tocilizumab compared with adalimumab. Four (2.5%) patients in the tocilizumab arm and two (1.2%) patients in the adalimumab arm experienced CTC grade 3 or 4 neutrophil count decreases. Eleven (6.8%) patients in the tocilizumab arm and five (3.1%) patients in the adalimumab arm experienced ALT increases of CTC grade 2 or higher.
The mean LDL increase from baseline was 0.64 mmol/L (25 mg/dL) for patients in the tocilizumab arm and 0.19 mmol/l (7 mg/dL) for patients in the adalimumab arm. The safety observed in the tocilizumab arm was consistent with the known safety profile of tocilizumab and no new or unexpected adverse drug reactions were observed (see Table 1) (see section 3.1.2 Clinical/Efficacy Studies).

**Patients Treated with Subcutaneous Tocilizumab (approved and not available in India)**

The safety of subcutaneous tocilizumab in RA was studied in SC-I. The study compared the efficacy and safety of tocilizumab 162 mg administered every week SC versus 8 mg/kg IV in 1262 subjects with adult RA. All patients in the study received background non-biologic DMARD(s). The safety and immunogenicity observed for tocilizumab administered SC was consistent with the known safety profile of IV tocilizumab and no new or unexpected adverse drug reactions were observed (see Table 1). A higher frequency of injection site reactions was observed in the SC arms compared with placebo SC injections in the IV arms (see section 3.1.2 Clinical/Efficacy Studies).

### Injection Site Reactions (ISRs)

During the 6-month controlled period, in SC-I, the frequency of injection site reactions was 10.1% (64/631) and 2.4% (15/631) for the SC tocilizumab and the SC placebo (IV group) weekly injections, respectively. These injection site reactions (including erythema, pruritus, pain and haematoma) were mild to moderate in severity. The majority was resolved without any treatment and none necessitated drug discontinuation.

### Immunogenicity

In SC-I, a total of 625 patients treated with tocilizumab 162 mg weekly were tested for anti-tocilizumab antibodies in the 6 month controlled period. Five patients (0.8%) developed positive anti-tocilizumab antibodies; of these, all developed neutralizing anti-tocilizumab antibodies.

A total of 1454 SC tocilizumab all exposure patients have been tested for anti-tocilizumab antibodies, thirteen patients (0.9%) developed positive anti-tocilizumab antibodies, and of these 12 patients (0.8%) developed neutralizing anti-tocilizumab antibodies.

No correlation of antibody development to clinical response or adverse events was observed.

### Polycarticular Juvenile Idiopathic Arthritis

The safety profile of tocilizumab was studied in 240 pediatric patients with pJIA. In Study WA19977, 188 patients, (2 to 17 years of age), were treated with IV tocilizumab. The total patient exposure in the tocilizumab all exposure population was 184.4 patient years. In general, the safety profile observed in patients with pJIA was consistent with the known safety profile of tocilizumab with the exception of ISRs (see Undesirable Effects section).

### Infections

Infections are the most common observed events in pJIA. The rate of infections in the PJA IV tocilizumab all exposure population was 163.7 per 100 patient years. The most common events observed were nasopharyngitis and upper respiratory tract infections. The rate of serious infections was numerically higher in patients weighing below 30 kg treated with 10 mg/kg tocilizumab (12.2 per 100 patient years) compared to patients weighing ≥30 kg, treated with 8 mg/kg Tocilizumab (4.0 per 100 patient years). The incidence of infections leading to dose interruptions was also numerically higher in patients weighing below< 30 kg treated with 10 mg/kg tocilizumab (21.4%) compared to patients weighing ≥30 kg, treated with 8 mg/kg tocilizumab (7.6%).

### Infusion Reactions

In pJIA patients, infusion related reactions are defined as all events occurring during or within 24 hours of an infusion with IV tocilizumab. In the tocilizumab all exposure population, 11 patients (5.9%) experienced infusion reactions during the infusion, and 38 patients (20.2%) experienced an event within 24 hours of an infusion. The most common events occurring during infusion were headache, nausea and hypotension and within 24 hours of infusion were dizziness and hypotension. In general, the adverse drug reactions observed during or within 24 hours of an infusion were similar in nature to those seen in RA and sJIA patients (see Undesirable Effects section).
No clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation were reported.

**Injection Site Reactions**
A total of 28.8% (15/52) pJIA patients experienced ISRs to SC tocilizumab. These ISRs occurred in 44% of patients >30 kg compared to 14.8% of patients below 30 kg. The most common ISRs were injection site erythema, swelling, hematoma, pain and pruritis. All ISRs reported were non-serious Grade 1 events, and none of the ISRs required patient withdrawal from treatment or dose interruption.

**Immunogenicity**
Across the two studies in pJIA patients, a total of four patients (0.5% in the IV Study WA19977 developed positive neutralizing anti-tocilizumab antibodies without developing a serious or clinically significant hypersensitivity reaction. Of these 4 patients, 2 subsequently withdrew from the study. No correlation between antibody development and clinical response or adverse events was observed.

**Systemic Juvenile Idiopathic Arthritis**
The safety profile of tocilizumab in sJIA was studied in 163 pediatric patients. In Study WA18221 (12-week trial and long term extension), 112 pediatric patients 2 to 17 years of age were treated with IV tocilizumab. In general, the adverse drug reactions in patients with sJIA were similar in type to those seen in RA patients (see Undesirable Effects section above).

**Infections**
In the 12 week controlled trial (Study WA 18221), the rate of all infections in the IV tocilizumab group was 344.7 per 100 patient-years and 287.0 per 100 patient-years in the placebo group. In the open label extension study (Part II) the overall rate of infections remained similar at 306.6 per 100 patient-years.

In the 12 week controlled trial the rate of serious infections in the IV tocilizumab group was 11.5 per 100 patient years. In the open label extension study the overall rate of serious infections remained stable at 11.3 per 100 patient years. Reported serious infections were similar to those seen in RA patients with the addition of varicella and otitis media.

**Infusion Reactions**
For sJIA patients, infusion related reactions are defined as all events occurring during or within 24 hours of an infusion with IV tocilizumab. In the 12 week controlled trial (Study WA18221), four percent (4.0%) of patients from the tocilizumab group experienced events occurring during infusion, one event (angioedema) was considered serious and life-threatening, and the patient was discontinued from study treatment.

In the 12 week controlled trial experience, 16% of patients in the IV tocilizumab group and 5.4% of patients in the placebo group experienced an event within 24 hours of infusion. In the tocilizumab group, the events included, but not limited to rash, urticaria, diarrhoea, epigastric discomfort, arthralgia and headache. One of these events, (urticaria) was considered serious.

Clinically significant hypersensitivity reactions associated with IV tocilizumab and requiring treatment discontinuation, were reported in 1 out of 112 patients (<below 1%) treated with tocilizumab during the controlled and open-label parts of the clinical trial.

**Injection Site Reactions (ISRs)**
In Study WA28118, a total of 41.2% (21/51) sJIA patients experienced ISRs to SC tocilizumab. The most common ISRs were erythema, pruritus, pain, and swelling at the injection site. The majority of ISRs reported were Grade 1 events and all ISRs reported were non-serious and none of the ISRs required patient withdrawal from treatment or dose interruption.

**Immunogenicity**
In Study WA 18221, All 112 patients were tested for anti-tocilizumab antibodies at baseline. Two patients developed positive anti-tocilizumab antibodies with one of these patients having a hypersensitivity reaction leading to withdrawal. In Study WA28118, 46 of the 51 (90.2%) patients tested for anti-tocilizumab antibodies at baseline had at least one post-
baseline screening assay result. No patient developed positive anti-tocilizumab antibodies post-baseline

**Laboratory Abnormalities**

**Haematological abnormalities:**

**Neutrophils**
There was no clear relationship between decreases in neutrophils below $1 \times 10^9$/L and the occurrence of serious infections in any of the indications.

**Rheumatoid Arthritis**

**Intravenous Administration:**
In the 6-month controlled trials decreases in neutrophil counts below $1 \times 10^9$/L occurred in 3.4% of patients on tocilizumab 8 mg/kg + DMARD compared to below 0.1% of patients on placebo + DMARD. Approximately half of the instances of ANC below $1 \times 10^9$/L occurred within 8 weeks after starting therapy. Decreases below $0.5 \times 10^9$/L were reported in 0.3% patients receiving tocilizumab 8 mg/kg + DMARD (see sections 2.2 Dosage and Administration, 2.4.4 Laboratory Tests).

In the all control and all exposure population, the pattern and incidence of decreases in neutrophil counts remained consistent with what was seen in the 6-month controlled clinical trials.

**Subcutaneous Administration (approved and not available in India):**
During routine laboratory monitoring in the tocilizumab 6-month controlled period of clinical trial SC-I, a decrease in neutrophil count below $1 \times 10^9$/L occurred in 2.9% of patients on tocilizumab 162 mg SC weekly.

**Polyarticular Juvenile Idiopathic Arthritis**

**Intravenous Administration**
During routine laboratory monitoring in the tocilizumab all exposure population, a decrease in neutrophil count below $1 \times 10^9$/L occurred in 3.7% of patients treated with IV tocilizumab.

**Systemic Juvenile Idiopathic Arthritis**

**Intravenous Administration:**
During routine laboratory monitoring in the 12 week controlled trial (Study WA18221), a decrease in neutrophil counts below $1 \times 10^9$/L occurred in 7% of patients in the IV tocilizumab group, and in none in the placebo group.

In the open-label extension study decreases in neutrophil counts below $1 \times 10^9$/L, occurred in 15% of the tocilizumab group.

In the 52-week open-label trial (Study WA28118), neutrophil count decrease below $1 \times 10^9$/L occurred in 23.5% of patients treated with SC tocilizumab

**Platelets**

**Rheumatoid Arthritis**

**Intravenous Administration:**
In the 6-month controlled trials decreases in platelet counts below $100 \times 10^3$/μl occurred in 1.7% of patients on tocilizumab 8 mg/kg plus DMARDs compared to below 1% on placebo plus DMARDs. These decreases occurred without associated bleeding events (see sections 2.2 Dosage and Administration, 2.4.1 Warnings and Precautions).

In the all control and all exposure population, the pattern and incidence of decreases in platelet counts remained consistent with what was seen in the 6-month controlled clinical trials.

**Subcutaneous Administration (approved and not available in India):**
During routine laboratory monitoring in the tocilizumab 6-month controlled period of clinical trial SC-I, none of the patients had a decrease in platelet count to $\leq 50 \times 10^3$/μL.

**Polyarticular Juvenile Idiopathic Arthritis**

**Intravenous Administration:**
During routine laboratory monitoring in the tocilizumab all exposure population, a decrease in platelet count to $\leq 50 \times 10^3$/μL.
10^3 / μL occurred in 1% of patients treated with IV tocilizumab without associated bleeding events.

**Systemic Juvenile Idiopathic Arthritis**

**Intravenous Administration:**
During routine laboratory monitoring in the 12 week controlled trial (Study WA18221), 3% of patients in the placebo group and 1% in the IV tocilizumab group had a decrease in platelet count to ≤ 100 × 10^3 / μL.

In the open-label extension study (WA18221) decreases in platelet counts below 100 x 10^3 / μL occurred in 3% of patients of the IV tocilizumab group, without associated bleeding events.

**Liver Enzyme elevations**

**Rheumatoid Arthritis**

**Intravenous Administration:**
During the 6-month controlled trials transient elevations in ALT/AST above 3 x ULN were observed in 2.1% of patients on tocilizumab 8 mg/kg compared to 4.9% of patients on MTX, and in 6.5% of patients who received tocilizumab 8 mg/kg + DMARD compared to 1.5% of patients on placebo + DMARDs. The addition of potentially hepatotoxic drugs (e.g. MTX) to tocilizumab monotherapy resulted in increased frequency of these elevations. Elevations of ALT/AST above 5 x ULN were observed in 0.7% of tocilizumab monotherapy patients and 1.4% of tocilizumab + DMARD patients, the majority of whom were discontinued from tocilizumab treatment (see section 2.2 Dosage and Administration, 2.4.4 Laboratory Tests).

During routine laboratory monitoring, the incidence of indirect bilirubin greater than the upper limit of normal was 6.2% in patients treated with 8 mg/kg Tocilizumab + DMARD in the all control population.

In the all control and all exposure population, the pattern and incidence of elevations in ALT/AST remained consistent with what was seen in the 6-month controlled clinical trials.

In Study VI, MTX-naïve adult patients with moderate to severe, active early RA (mean disease duration ≤ 6 months) experienced more transient elevations in ALT above 3xULN compared with the all control population. This was observed in both tocilizumab treated patients and MTX monotherapy patients.

In Study WA25204, of the 1538 patients with moderate to severe RA (see Section 3.1.2 Clinical/Efficacy Studies) and treated with tocilizumab, elevations in ALT or AST >3 x ULN occurred in 5.3% and 2.2% patients, respectively. One serious event of drug induced hepatitis with hyperbilirubinemia was reported in association with tocilizumab treatment (see section 2.4.1 Warnings and Precautions).

**Subcutaneous Administration (approved and not available in India):**
During routine laboratory monitoring in the tocilizumab 6-month controlled period of clinical trial SC-I, elevation in ALT or AST ≥3 x ULN occurred in 6.5% and 1.4% of patients, respectively on SC weekly.

**Polyarticular Juvenile Idiopathic Arthritis**

**Intravenous Administration:**
During routine laboratory monitoring in the tocilizumab all exposure population, elevation in ALT or AST ≥3 x ULN occurred in 3.7% and below 1% of patients, respectively.

**Systemic Juvenile Idiopathic Arthritis**

**Intravenous Administration:**
During routine laboratory monitoring in the 12 week controlled trial, elevation in ALT or AST ≥ 3xULN occurred in 5% and 3% of patients, respectively, in the Tocilizumab group, and in 0% of placebo patients.

In the ongoing open-label extension study, elevation in ALT or AST ≥ 3xULN occurred in 12% and 4% of patients, respectively, in the tocilizumab group.

**Elevations in Lipid parameters**

**Rheumatoid Arthritis**

**Intravenous Administration:**
During routine laboratory monitoring in the 6 month controlled trials, elevations in lipid parameters (total cholesterol,
LDL, HDL, triglycerides) were observed in patients treated with tocilizumab. Approximately 24% of patients receiving tocilizumab in clinical trials experienced sustained elevations in total cholesterol above 6.2 mmol/L (240 mg/dL), with 15% experiencing a sustained increase in LDL to ≥ 4.1 mmol/L (160 mg/dL).

In the majority of patients there was no increase in atherogenic indices, and elevations in total cholesterol responded to treatment with lipid-lowering agents.

In the all control and all exposure population, the pattern and incidence of elevations in lipid parameters remained consistent with what was seen in the 6month controlled clinical trials.

**Subcutaneous Administration (approved and not available in India):**
During routine laboratory monitoring in the tocilizumab 6-month controlled period of clinical trial SC-I, 19% of patients on SC weekly experienced sustained elevations in total cholesterol above 6.2 mmol/L (240 mg/dL), with 9% experiencing a sustained increase in LDL to ≥ 4.1 mmol/L (160 mg/dL) on SC weekly.

**Polyarticular Juvenile Idiopathic Arthritis**

**Intravenous Administration:**
During routine laboratory monitoring in the IV tocilizumab Study WA19977 3.4 % and 10.4% of patients experienced a post-baseline elevation of their LDL cholesterol value to ≥ 130 mg/dL and total cholesterol value to ≥ 200 mg/dL at any time during the study treatment, respectively. In the SC tocilizumab Study WA28117, 14.3% and 12.8% of patients experienced a post-baseline elevation of their LDL-cholesterol value to ≥ 130 mg/dL and total cholesterol value to ≥ 200 mg/dL at any time during study treatment, respectively.

**Systemic Juvenile Idiopathic Arthritis**

**Intravenous Administration:**
During routine laboratory monitoring in the 12-week controlled trial (Study WA18221), 13.4% and 33.3% of patients experienced a post-baseline elevation of their LDL-cholesterol value to ≥ 130 mg/dL and total cholesterol value to ≥ 200 mg/dL, respectively.

In the open-label extension study (WA18221), 13.2% and 27.7% of patients experienced a post-baseline elevation of their LDL-cholesterol value to ≥ 130 mg/dL and total cholesterol value to ≥ 200 mg/dL, respectively.

In the 52-week open-label trial (Study WA28118), 23.4% and 35.4% of patients experienced a post-baseline elevation of their LDL-cholesterol value to ≥ 130 mg/dL and total cholesterol value to ≥ 200 mg/dL, respectively.

**2.6.2 Post Marketing**
The following adverse drug reactions have been identified from post marketing experience with tocilizumab (Table 1a) based on spontaneous case reports, literature cases and cases from non-interventional study programs. Adverse drug reactions are listed according to system organ classes in MedDRA and the corresponding frequency category estimation for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

<table>
<thead>
<tr>
<th>Adverse reaction (MedDRA)</th>
<th>Incidence</th>
<th>Frequency Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaphylaxis (fatal)1, 2</td>
<td>Not observed in clinical development</td>
<td>Rare</td>
</tr>
</tbody>
</table>
### Adverse reaction (MedDRA)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Incidence¹</th>
<th>Frequency Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stevens-Johnson syndrome</td>
<td>Not observed in clinical development</td>
<td>Rare</td>
</tr>
<tr>
<td>Hypofibrinogenemia</td>
<td>1.3 per 100 patient years</td>
<td>Common</td>
</tr>
<tr>
<td>Drug-induced liver injury</td>
<td>0.2 per 100 patient years</td>
<td>Rare</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>0.035 per 100 patient years</td>
<td>Rare</td>
</tr>
<tr>
<td>Hepatic failure</td>
<td>0.004 per 100 patient years</td>
<td>Very Rare</td>
</tr>
<tr>
<td>Jaundice</td>
<td>Not observed in clinical trials</td>
<td>Rare</td>
</tr>
</tbody>
</table>

¹ See section 2.3 Contraindications

2 See section 2.4.1 Warnings and Precautions, General

3 This adverse reaction was identified through post marketing surveillance but not observed in clinical trials. The frequency category was estimated as the upper limit of the 95% confidence interval calculated on the basis of the total number of patients exposed to TCZ in clinical trials.

4 Incidence rate calculated based on all-exposure data obtained from relevant completed clinical trials for all indications.

2.7 Overdose

There are limited data available on overdosage with tocilizumab. One case of accidental overdose was reported in which a patient with multiple myeloma received a single dose of 40 mg/kg IV. No adverse drug reactions were observed. No serious adverse drug reactions were observed in healthy volunteers who received a single dose up to 28 mg/kg IV, although dose-limiting neutropenia was observed.

2.8 Interactions with Other Medicinal Products and Other Forms of Interaction

Population pharmacokinetic analyses did not detect any effect of MTX, nonsteroidal anti-inflammatory drugs or corticosteroids on tocilizumab clearance in RA patients.

Concomitant administration of a single dose of 10 mg/kg tocilizumab with 10-25 mg MTX once weekly had no clinically significant effect on MTX exposure.

Tocilizumab has not been studied in combination with other biological DMARDs.

The expression of hepatic CYP450 enzymes is suppressed by cytokines, such as IL-6, that stimulate chronic inflammation. Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as tocilizumab is introduced.

**In vitro** studies with cultured human hepatocytes demonstrated that IL-6 caused a reduction in CYP1A2, CYP2C9, CYP2C19, and CYP3A4 enzyme expression. Tocilizumab normalizes expression of these enzymes.

The effect of tocilizumab on CYP enzymes (except CYP2C19 and CYP2D6) is clinically relevant for CYP450 substrates with a narrow therapeutic index, and/or where the dose is individually adjusted.

In a study in RA patients, levels of simvastatin (CYP3A4) were decreased by 57% one week following a single dose of tocilizumab, to the level similar or slightly higher than those observed in healthy subjects.

When starting or stopping therapy with tocilizumab, patients taking medicinal products, which are individually dose-
adjusted and are metabolised via CYP450 3A4, 1A2, or 2C9 (e.g. atorvastatin, calcium channel blockers, theophylline, warfarin, phenytoin, ciclosporin, or benzodiazepines) should be monitored as doses of these products may need to be adjusted to maintain their therapeutic effect. Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may persist for several weeks after stopping therapy.

### 3. Pharmacological Properties And Effects

#### 3.1 Pharmacodynamic Properties

In clinical studies with tocilizumab in RA, rapid decreases in C-Reactive Protein (CRP), erythrocyte sedimentation rate (ESR), serum amyloid A and fibrinogen were observed. Increases in haemoglobin levels were observed, through tocilizumab decreasing the IL-6 driven effects on hepcidin production to increase iron availability.

In study WA28119, similar rapid decreases in CRP and ESR were observed along with slight increases in mean corpuscular haemoglobin concentration.

In healthy subjects administered tocilizumab in doses from 2 to 28 mg/kg, absolute neutrophil counts decreased to their lowest 3 to 5 days following administration. Thereafter, neutrophils recovered towards baseline in a dose dependent manner. Rheumatoid arthritis patients demonstrated a similar pattern of absolute neutrophil counts following tocilizumab administration (see section 2.4.1 Warning and Precautions, General).

#### 3.1.1 Mechanism of action

Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) IgG1 subclass. Tocilizumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit sIL-6R and mIL-6R-mediated signaling. IL-6 is a multifunctional cytokine, produced by a variety of cell types involved in local paracrine function as well as regulation of systemic physiological and pathological processes such as induction of immunoglobulin secretion, T-cell activation, induction of hepatic acute phase proteins and stimulation of haematopoiesis. IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis, and neoplasia.

The possibility exists for tocilizumab to affect host defences against infections and malignancies. The role of IL-6 receptor inhibition in the development of malignancies is not known.

#### 3.1.2 Clinical / Efficacy Studies

**Rheumatoid Arthritis**

The efficacy of intravenously administered tocilizumab in alleviating the signs and symptoms of rheumatoid arthritis was assessed in five randomised, double-blind, multicentre studies. Studies I-V required patients ≥ age 18 with active rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria and who had at least 8 tender and 6 swollen joints at baseline.

Tocilizumab was administered intravenously every 4 weeks as monotherapy (Study I), in combination with MTX (Studies II, III, V) or with other disease-modifying antirheumatic drugs (DMARDs) (Study IV).

Study I evaluated 673 patients who had not been treated with MTX within 6 months prior to randomisation, and who had not discontinued previous MTX treatment as a result of clinically important toxic effects or lack of response. The majority (67%) of patients were MTX naïve. Doses of 8 mg/kg of tocilizumab were given every four weeks as monotherapy. The comparator group was weekly MTX (dose titrated from 7.5 mg to a maximum of 20 mg weekly over an 8 week period). The primary endpoint was the proportion of patients who achieved an ACR20 response at week 24.

Study II, a 2 year study, evaluated 1196 patients who had an inadequate clinical response to MTX. Doses of 4 or 8 mg/kg of tocilizumab or placebo were given every four weeks as blinded therapy for 52 weeks, in combination with stable MTX (10 - 25 mg weekly). The primary endpoint at week 24 was the proportion of patients who achieved an ACR 20 response
criteria. At week 52 the co-primary endpoints were prevention of joint damage and improvement in physical function. Study III evaluated 623 patients who had an inadequate clinical response to MTX. Doses of 4 or 8 mg/kg tocilizumab or placebo were given every four weeks, in combination with stable MTX (10 - 25 mg weekly). Study IV evaluated 1220 patients who had an inadequate response to their existing rheumatologic therapy, including one or more DMARDs. Doses of 8 mg/kg tocilizumab or placebo were given every four weeks, in combination with the stable DMARD. Study V evaluated 499 patients who had an inadequate clinical response or were intolerant to one or more anti-TNF therapies. The anti-TNF agent was discontinued prior to randomisation. Doses of 4 or 8 mg/kg of tocilizumab or placebo were given every four weeks, in combination with stable MTX (10 - 25 mg weekly). The primary endpoint for studies III-V was the proportion of patients who achieved an ACR20 response at week 24. The percent of patients achieving ACR 20, 50 and 70 responses in Studies I to V are shown in Table 2.

**Table 2: ACR responses in MTX/Placebo Controlled Trials (Percent of Patients)**

<table>
<thead>
<tr>
<th>Study</th>
<th>MTX Naive Inadequate Response to MTX</th>
<th>Inadequate Response to MTX</th>
<th>Inadequate Response to DMARD</th>
<th>Inadequate Response to TNF Blocking Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response Rate</td>
<td>TCZ 8 mg/kg N=286</td>
<td>MTX N=284</td>
<td>TCZ 8 mg/kg +MTX N= 398</td>
<td>Placebo + MTX N=393</td>
</tr>
<tr>
<td>ACR20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 24</td>
<td>70%***</td>
<td>52%</td>
<td>56%***</td>
<td>27%</td>
</tr>
<tr>
<td>Week 52</td>
<td>56%***</td>
<td>25%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR50</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 24</td>
<td>44%**</td>
<td>33%</td>
<td>32%***</td>
<td>10%</td>
</tr>
<tr>
<td>Week 52</td>
<td>36%***</td>
<td>10%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR70</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 24</td>
<td>28%**</td>
<td>15%</td>
<td>13%***</td>
<td>2%</td>
</tr>
<tr>
<td>Week 52</td>
<td>20%***</td>
<td>4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCR† by week 52</td>
<td>7%</td>
<td>1%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TCZ = tocilizumab

* p<0.05, tocilizumab vs. placebo+MTX/DMARD
** p<0.01, tocilizumab vs. placebo+MTX/DMARD
*** p<0.0001, tocilizumab vs. placebo+MTX/DMARD
† MCR = major clinical response, defined as an ACR70 response maintained for any 24 consecutive weeks or more.

In all studies, 8 mg/kg tocilizumab-treated patients had statistically significant higher ACR 20, 50, 70 response rates at 6 months compared to control (Table 3). The treatment effect was similar in patients independent of rheumatoid factor status, age, gender, race, number of prior treatments or disease status. Time to onset was rapid (as early as week 2) and the magnitude of response continued to improve with duration of treatment. Continued durable responses were seen for over 3 years in the ongoing open label extension studies of Studies I - V.

In the 8 mg/kg tocilizumab-treated patients significant improvements were noted on all individual components of the ACR response (tender and swollen joint counts, patient and physician global assessment, disability index scores (HAQ), pain assessment and CRP compared to patients receiving placebo +MTX/DMARDs in all studies.

Tocilizumab 8 mg/kg treated patients had a statistically significantly greater reduction in disease activity score (DAS28) than patients treated with placebo+DMARD. A good to moderate EULAR response was achieved by significantly more tocilizumab treated patients compared to patients treated with placebo+DMARD (Table 3).

<table>
<thead>
<tr>
<th>Study I</th>
<th>Study II</th>
<th>Study III</th>
<th>Study IV</th>
<th>Study V</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX Naive</td>
<td>Inadequate Response to MTX</td>
<td>Inadequate Response to MTX</td>
<td>Inadequate Response to MTX</td>
<td>Inadequate Response to TNF Blocking Agent</td>
</tr>
<tr>
<td>TCZ 8 mg/kg N=286</td>
<td>TCZ 8 mg/kg +MTX N= 398</td>
<td>Placebo + MTX N= 205</td>
<td>TCZ 8 mg/kg +DMARD N=803</td>
<td>Placebo + MTX N=158</td>
</tr>
<tr>
<td>MTX N=284</td>
<td>TCZ 8 mg/kg +MTX N= 398</td>
<td>Placebo + MTX N= 205</td>
<td>TCZ 8 mg/kg +MTX N= 205</td>
<td>Placebo + DMARD N=413</td>
</tr>
<tr>
<td>Placebo + MTX N= 205</td>
<td>Placebo + DMARD N=413</td>
<td>Placebo + DMARD N=413</td>
<td>Placebo + DMARD N=413</td>
<td></td>
</tr>
</tbody>
</table>

Table 3: Cross-Study Comparison of DAS and EULAR Responses at Week 24

<table>
<thead>
<tr>
<th>Change in DAS28</th>
<th>Week 24</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCZ 8 mg/kg</td>
<td>-3.31 (0.12)</td>
</tr>
<tr>
<td>MTX</td>
<td>-2.05 (0.12)</td>
</tr>
<tr>
<td>Placebo + MTX</td>
<td>-3.11 (0.09)***</td>
</tr>
<tr>
<td>Placebo + MTX</td>
<td>-1.45 (0.11)</td>
</tr>
<tr>
<td>Placebo + MTX</td>
<td>-3.43 (0.12)***</td>
</tr>
<tr>
<td>Placebo + MTX</td>
<td>-1.55 (0.15)</td>
</tr>
<tr>
<td>Placebo + MTX</td>
<td>-3.17 (0.07)***</td>
</tr>
<tr>
<td>Placebo + MTX</td>
<td>-1.16 (0.09)</td>
</tr>
<tr>
<td>Placebo + MTX</td>
<td>-3.16 (0.14)***</td>
</tr>
<tr>
<td>Placebo + MTX</td>
<td>-0.95 (0.22)</td>
</tr>
</tbody>
</table>

DAS<2.6 response (%)

<table>
<thead>
<tr>
<th>Week 24</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCZ 8 mg/kg</td>
</tr>
<tr>
<td>MTX</td>
</tr>
<tr>
<td>Placebo + MTX</td>
</tr>
<tr>
<td>Placebo + MTX</td>
</tr>
<tr>
<td>Placebo + MTX</td>
</tr>
<tr>
<td>Placebo + MTX</td>
</tr>
<tr>
<td>Placebo + MTX</td>
</tr>
<tr>
<td>Placebo + MTX</td>
</tr>
<tr>
<td>Placebo + MTX</td>
</tr>
<tr>
<td>Placebo + MTX</td>
</tr>
</tbody>
</table>

EULAR response (%)

| None        | 18% |
| Moderate    | 42% |
| Good†       | 40% |

TCZ = tocilizumab

†The p value compares across all the EULAR categories

* p<0.05, tocilizumab vs. placebo+MTX/DMARD
** p<0.01, tocilizumab vs. placebo+MTX/DMARD
*** p<0.0001, tocilizumab vs. placebo+MTX/DMARD
≠ In study II, 47% of patients achieved a DAS28 < 2.6 at 52 weeks compared to 33% of patients at week 24

Major Clinical Response
After 2 years of treatment with tocilizumab/MTX, 14% of patients achieved a major clinical response (maintenance of an ACR70 response for 24 weeks or more).

Radiographic response - Intravenous administration
In Study II, in patients with an inadequate response to MTX, inhibition of structural joint damage was assessed radiographically and expressed as change in modified Sharp score and its components, the erosion score and joint space...
narrowing score. Inhibition of joint structural damage was shown with significantly less radiographic progression in patients receiving tocilizumab compared to control. In the open-label extension of Study II the inhibition of progression of structural joint damage in tocilizumab/MTX-treated patients was maintained in the second year of treatment.

Table 4: Radiographic mean changes over 52 and 104 weeks in Study II

<table>
<thead>
<tr>
<th></th>
<th>PBO + MTX (+option of TCZ from week 16)</th>
<th>TCZ 8 mg/kg + MTX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Changes from baseline to Week 52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>294</td>
<td>353</td>
</tr>
<tr>
<td>Total Sharp-Genant score</td>
<td>1.17</td>
<td>0.25</td>
</tr>
<tr>
<td>Erosion score</td>
<td>0.76</td>
<td>0.15</td>
</tr>
<tr>
<td>JSN score</td>
<td>0.41</td>
<td>0.10</td>
</tr>
<tr>
<td>Change from week 52 to week 104</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>294</td>
<td>353</td>
</tr>
<tr>
<td>Total Sharp-Genant score</td>
<td>0.79</td>
<td>0.12</td>
</tr>
<tr>
<td>Erosion score</td>
<td>0.48</td>
<td>0.07</td>
</tr>
<tr>
<td>JSN score</td>
<td>0.31</td>
<td>0.05</td>
</tr>
</tbody>
</table>

PBO - Placebo  
MTX - Methotrexate  
TCZ Tocilizumab  
JSN - Joint space narrowing

All data presented was read together in campaign 2 which consists of the evaluations of the baseline, week 24, week 52, week 80, week 104 and early withdrawal or escape therapy readings taken up to week 104 visit. Following 1 year of treatment with tocilizumab/MTX, 83% of patients had no progression of structural damage, as defined by a change in the Total Sharp Score (TSS) of zero or less, compared with 67% of placebo/MTX-treated patients. This remained consistent following 2 years of treatment (83%). Ninety three percent (93%) of patients had no progression between week 52 and week 104.

Quality of life outcomes – Intravenous administration  
Clinically significant improvements in disability index (HAQ-DI, Health Assessment Questionnaire Disability Index), fatigue (FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy Fatigue) and improvement in both the physical (PCS, Physical Component Summary) and mental health (MCS, Mental Component Summary) domains of the SF-36 (Short Form 36) were observed in patients treated with 8 mg/kg tocilizumab (monotherapy or combination with DMARDs) compared to patients treated with MTX/DMARDs (Table 6).
At week 24, the proportion of 8 mg/kg tocilizumab treated patients showing a clinically relevant improvement in HAQ-DI (defined as an individual total score decrease of >0.25), was significantly higher than among patients receiving placebo + MTX/DMARDs in all studies. During the open-label period of Study II the improvement in physical function has been maintained for up to 2 years.

Table 5: Comparison of SF-36, HAQ and FACIT-Fatigue Responses at Week 24

<table>
<thead>
<tr>
<th>Study</th>
<th>TCZ 8 mg/kg</th>
<th>MTX</th>
<th>TCZ 8 mg/kg + MTX</th>
<th>Placebo + MTX</th>
<th>TCZ 8 mg/kg + DMARD</th>
<th>Placebo + DMARD</th>
<th>TCZ 8 mg/kg + MTX</th>
<th>Placebo + MTX</th>
<th>TCZ 8 mg/kg + MTX</th>
<th>Placebo + MTX</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX-Naïve</td>
<td>N=286</td>
<td>N=284</td>
<td>N=398</td>
<td>N=393</td>
<td>N=205</td>
<td>N=204</td>
<td>N=413</td>
<td>N=170</td>
<td>N=158</td>
<td></td>
</tr>
<tr>
<td>Change in PCS</td>
<td>10.2 (0.7)</td>
<td>8.4 (0.7)</td>
<td>8.1 (0.7)</td>
<td>5.6 (0.7)</td>
<td>9.5 (0.8)**</td>
<td>5.0 (1.0)</td>
<td>8.9 (0.4)***</td>
<td>4.1 (0.6)</td>
<td>8.0 (0.9)**</td>
<td>2.2 (1.3)</td>
</tr>
<tr>
<td>Change in MCS</td>
<td>6.7 (0.9)</td>
<td>5.0 (0.9)</td>
<td>4.2 (0.8)</td>
<td>2.8 (0.9)</td>
<td>7.3 (1.1)**</td>
<td>2.7 (1.3)</td>
<td>5.3 (0.6)**</td>
<td>2.3 (0.7)</td>
<td>4.1 (1.3)</td>
<td>4.1 (1.9)</td>
</tr>
<tr>
<td>Change in HAQ-DI</td>
<td>-0.70 (0.05)</td>
<td>-0.52 (0.05)</td>
<td>-0.5 (0.04)**</td>
<td>-0.3 (0.04)</td>
<td>-0.55 (0.06)**</td>
<td>-0.34 (0.07)</td>
<td>-0.47 (0.03)***</td>
<td>-0.2 (0.03)</td>
<td>-0.39 (0.05)***</td>
<td>-0.05 (0.07)</td>
</tr>
<tr>
<td>Change in FACIT-Fatigue</td>
<td>9.3 (0.8)</td>
<td>7.0 (0.8)</td>
<td>6.4 (0.7)</td>
<td>5.4 (0.8)</td>
<td>8.6 (0.9)***</td>
<td>4.0 (1.0)</td>
<td>8.0 (0.5)***</td>
<td>3.6 (0.7)</td>
<td>8.8 (1.0)*</td>
<td>4.2 (1.6)</td>
</tr>
</tbody>
</table>

TCZ = tocilizumab
* p<0.05, tocilizumab vs. placebo+MTX/DMARD
** p<0.01, tocilizumab vs. placebo+MTX/DMARD
*** p<0.0001, tocilizumab vs. placebo+MTX/DMARD

In study II, changes in PCS, MCS and FACIT-Fatigue at 52 weeks were 10.1***, 5.4 and 8.4***, respectively, in the TCZ 8 mg/kg + MTX group compared to 5.6, 3.8 and 5.5, respectively, in the Placebo plus MTX group. At Week 52, the mean change in HAQ-DI was -0.58 in the TCZ 8 mg/kg + MTX group compared with -0.39 in the placebo + MTX group. The mean change in HAQ-DI was maintained at Week 104 in the TCZ 8 mg/kg + MTX group (-0.61).

Laboratory Evaluations
Treatment with 8 mg/kg tocilizumab in combination with DMARD/MTX or as monotherapy resulted in a highly statistically significant improvement in haemoglobin levels compared with placebo + MTX/DMARD (p<0.0001) at week 24. The greatest improvement was observed in patients with chronic anaemia associated with RA; mean haemoglobin levels increased by week 2 and remained within normal range through week 24.

A marked decrease in mean levels of acute phase reactants, CRP, ESR, and serum amyloid A occurred rapidly after
tocilizumab administration. Consistent with the effect on acute phase reactants, treatment with tocilizumab was associated with reduction in platelet count within the normal range.

MTX naïve, Early RA

Study VI, a 2 year study with the planned primary analysis at week 52 evaluated 1162 MTX-naïve adult patients with moderate to severe, active early RA (mean disease duration ≤ 6 months). This study evaluated the efficacy of IV tocilizumab 4 or 8 mg/kg every 4 weeks/MTX combination therapy, IV tocilizumab 8 mg/kg monotherapy and MTX monotherapy in reducing the signs and symptoms and rate of progression of joint damage for 104 weeks. The primary endpoint was the proportion of patients achieving DAS28 remission (DAS28 below 2.6) at week 24. A significantly higher proportion of patients in the tocilizumab 8 mg/kg + MTX and tocilizumab monotherapy groups met the primary endpoint compared with MTX alone. The tocilizumab 8 mg/kg + MTX group also showed statistically significant results across the key secondary endpoints. Numerically greater responses compared with MTX alone were observed in the tocilizumab 8 mg/kg monotherapy group in all secondary endpoints, including radiographic endpoints. In this study, ACR/EULAR remission (Boolean and Index) were also analysed as pre-specified exploratory endpoints, with higher responses observed in the tocilizumab groups. The results from study VI are shown in Table 7.

Table 6: Efficacy Results for Study VI (WA19926) on MTX-naïve, early RA patients

<table>
<thead>
<tr>
<th></th>
<th>TCZ 8 mg/kg + MTX N=290</th>
<th>TCZ 8 mg/kg + placebo N=292</th>
<th>Placebo + MTX N=287</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Endpoint</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28 Remission</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 24</td>
<td>130 (44.8)***</td>
<td>113 (38.7)***</td>
<td>43 (15.0)</td>
</tr>
<tr>
<td>Key Secondary Endpoints</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS 28 remission</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 52</td>
<td>142 (49.0)***</td>
<td>115 (39.4)</td>
<td>56 (19.5)</td>
</tr>
<tr>
<td>ACR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 24</td>
<td>216 (74.5)*</td>
<td>205 (70.2)</td>
<td>187 (65.2)</td>
</tr>
<tr>
<td>ACR50, n (%)</td>
<td>165 (56.9)**</td>
<td>139 (47.6)</td>
<td>124 (43.2)</td>
</tr>
<tr>
<td>ACR70, n (%)</td>
<td>112 (38.6)**</td>
<td>88 (30.1)</td>
<td>73 (25.4)</td>
</tr>
<tr>
<td>Week 52</td>
<td>195 (67.2)*</td>
<td>184 (63.0)</td>
<td>164 (57.1)</td>
</tr>
<tr>
<td>ACR50, n (%)</td>
<td>162 (55.9)**</td>
<td>144 (49.3)</td>
<td>117 (40.8)</td>
</tr>
<tr>
<td>ACR70, n (%)</td>
<td>125 (43.1)**</td>
<td>105 (36.0)</td>
<td>83 (28.9)</td>
</tr>
<tr>
<td>HAQ-DI (adjusted mean change from baseline)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 52</td>
<td>-0.81*</td>
<td>-0.67</td>
<td>-0.64</td>
</tr>
<tr>
<td>Radiographic Endpoints (mean change from baseline)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Week 52  mTSS  0.08***  0.26  1.14
Erosion Score  0.05**  0.15  0.63
JSN  0.03  0.11  0.51
Radiographic Non-Progression n (%) (change from baseline in mTSS of ≤0)  226 (83)‡  226 (82)‡  194 (73)
Exploratory Endpoints
Week 24: ACR/EULAR Boolean Remission, n (%)  47 (18.4)‡  38 (14.2)  25 (10.0)
ACR/EULAR Index Remission, n (%)  73 (28.5)‡  60 (22.6)  41 (16.4)
Week 52: ACR/EULAR Boolean Remission, n (%)  59 (25.7)‡  43 (18.7)  34 (15.5)
ACR/EULAR Index Remission, n (%)  83 (36.1)‡  69 (30.0)  49 (22.4)

All efficacy comparisons vs Placebo + MTX. ***p≤0.0001; **p<0.001; *p<0.05; ‡p-value < 0.05 vs. Placebo + MTX, but endpoint was exploratory (not included in the hierarchy of statistical testing and has therefore not been controlled for multiplicity)

Monotherapy: tocilizumab versus adalimumab
Study WA19924 evaluated 326 patients with RA who were intolerant of MTX or where continued treatment with MTX was considered inappropriate (including MTX inadequate responders). Patients in the tocilizumab arm received an intravenous (IV) infusion of tocilizumab (8 mg/kg) every 4 weeks (q4w) and a subcutaneous (SC) placebo injection every 2 weeks (q2w). Patients in the adalimumab arm received an adalimumab SC injection (40 mg) q2w plus an IV placebo infusion q4w.

A statistically significant superior treatment effect was seen in favour of tocilizumab over adalimumab in control of disease activity from baseline to week 24 for the primary endpoint of change in DAS28 and for all secondary endpoints (Table 8)

**Table 7: Efficacy Results for Study WA 19924**

<table>
<thead>
<tr>
<th></th>
<th>ADA + Placebo (IV)</th>
<th>TCZ + Placebo (SC)</th>
<th>p-value&lt;sup&gt;(a)&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Endpoint - Mean Change from baseline at Week 24</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28 (adjusted mean)</td>
<td>-1.8</td>
<td>-3.3</td>
<td></td>
</tr>
<tr>
<td>Difference in adjusted mean (95% CI)</td>
<td>-1.5 (-1.8, -1.1)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td><strong>Secondary Endpoints - Percentage of Responders at Week 24&lt;sup&gt;(b)&lt;/sup&gt;</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28 &lt; 2.6, n (%)</td>
<td>18 (10.5)</td>
<td>65 (39.9)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>
Cardiovascular Outcomes

Study WA25204 was a randomized, open-label (sponsor-blinded), 2-arm parallel group, multi-center, non-inferiority, cardiovascular (CV) outcomes trial in patients with a diagnosis of moderate to severe RA. This CV safety study was designed to exclude a moderate increase in CV risk in patients treated with TCZ compared with a TNF inhibitor standard of care (etanercept).

The study included 3,080 seropositive RA patients with active disease and an inadequate response to non-biologic disease-modifying anti-rheumatic drugs, who were aged ≥50 years with at least one additional CV risk factor beyond RA. Patients were randomized 1:1 to IV TCZ 8 mg/kg Q4W or SC ETA 50 mg QW and followed for an average of 3.2 years. The primary endpoint was the comparison of the time-to-first occurrence of any component of a composite of major adverse CV events (MACE; non-fatal myocardial infarction, non-fatal stroke, or CV death), with the final intent-to-treat analysis based on a total of 161 confirmed CV events reviewed by an independent and blinded adjudication committee. Non-inferiority of TCZ to ETA for cardiovascular risk was determined by excluding a >80% relative increase in the risk of MACE. The primary endpoint was met such that a >43% increase in the risk of MACE could be excluded (hazard ratio comparing TCZ to ETA = 1.05; 95% CI = 0.77, 1.43).

Polyarticular-course Juvenile Idiopathic Arthritis (pJIA)

The efficacy of intravenous tocilizumab was assessed in a three-part study including an open-label extension in children with active polyarticular juvenile idiopathic arthritis (pJIA). Part I consisted of a 16-week active tocilizumab treatment lead-in period (n=188) followed by Part II, a 24-week randomized double-blind placebo-controlled withdrawal period (ITT, n=163), followed by Part III, a 64-week open-label period. Eligible patients ≥ 30 kg received tocilizumab at 8 mg/kg for 4 doses. Patients below 30 kg were randomized 1:1 to receive either tocilizumab 8 mg/kg or 10 mg/kg IV every 4 weeks for 4 doses. Patients who completed Part I of the study and achieved at least a JIA ACR30 response at week 16 compared to baseline entered the blinded withdrawal period (Part II) of the study. In Part II, patients were randomized to tocilizumab (same dose received in Part I) or placebo in a 1:1 ratio was stratified by concurrent methotrexate use and concurrent corticosteroid use. Each patient continued in Part II of the study until Week 40 or until the patient satisfied JIA ACR30 flare criteria (relative to Week 16) and qualified for escape.

The primary endpoint was the proportion of patients with a JIA ACR30 flare at week 40 relative to week 16. Forty-eight percent (48.1%, 39/81) of the patients treated with placebo flared compared with 25.6% (21/82) of TCZ-treated patients. These proportions were statistically significantly different (p=0.0024).

At the conclusion of Part I, JIA ACR 30/50/70/90 responses were 89.4%, 83.0%, 62.2%, and 26.1%, respectively. During the withdrawal phase (Part II), the percent of patients achieving JIA ACR 30, 50, and 70 responses at Week 40 relative to baseline are shown in the table below.

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>N (%)</th>
<th>N (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAS28 ≤ 3.2</td>
<td>32 (19.8)</td>
<td>84 (51.5)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>ACR20 response</td>
<td>80 (49.4)</td>
<td>106 (65.0)</td>
<td>0.0038</td>
</tr>
<tr>
<td>ACR50 response</td>
<td>45 (27.8)</td>
<td>77 (47.2)</td>
<td>0.0002</td>
</tr>
<tr>
<td>ACR70 response</td>
<td>29 (17.9)</td>
<td>53 (32.5)</td>
<td>0.0023</td>
</tr>
</tbody>
</table>

a p value is adjusted for region and duration of RA for all endpoints and additionally baseline value for all continuous endpoints.

b Non-responder Imputation used for missing data. Multiplicity controlled using Bonferroni-Holm Procedure

Table 8: JIA ACR Response Rates at Week 40 Relative to Baseline (Percent of Patients)
A 52-week, open-label, multi-centre, PK/PD and safety study (WA28118) was conducted in paediatric patients with sJIA, aged 1 to 17 years, to determine the appropriate SC dose of TCZ that achieved comparable PK/PD and safety profiles to the IV regimen.

Eligible patients received tocilizumab dosed according to body weight (BW), with patients weighing >30 kg (n = 25) dosed with 162 mg of tocilizumab every 2 weeks (Q2W) and patients weighing below 30 kg (n = 27) dosed with 162 mg of TCZ every 3 weeks (Q3W) for 52 weeks. Of these 52 patients, 37 (71%) were naive to tocilizumab and 15 (29%) had been receiving IV TCZ and switched to SC TCZ at baseline.

### Systemic Juvenile Idiopathic Arthritis (sJIA)

The efficacy of intravenous tocilizumab for the treatment of active sJIA was assessed in a 12-week randomized, double blind, placebo-controlled, parallel group, 2-arm study. Patients (treated with or without MTX) were randomized (TCZ:placebo = 2:1) to one of two treatment groups, 75 patients received tocilizumab infusions every two weeks either 8 mg/kg for patients ≥30kg or 12 mg/kg for patients below 30 kg and 37 patients were assigned to receiving placebo infusions every two weeks. Corticosteroid tapering could occur from week six for patients who achieved a JIA ACR70 response. After 12 weeks or at the time of escape, due to disease worsening, patients were treated in the open label extension phase at weight appropriate dosing.

The primary endpoint was the proportion of patients with at least 30% improvement in JIA ACR core set (JIA ACR30 response) at Week 12 and absence of fever (no temperature recording ≥ 37.5°C in the preceding 7 days). Eighty five percent (64/75) of the patients treated with TCZ and 24.3% (9/37) of placebo patients achieved this endpoint. These proportions were highly significantly different (p<0.0001).

The percent of patients achieving JIA ACR 30, 50, 70 and 90 responses are shown in the table below. Responses are maintained in the open label extension phase.

<table>
<thead>
<tr>
<th>Response Rate</th>
<th>TCZ N=75</th>
<th>Placebo N=37</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR 30</td>
<td>90.7%*</td>
<td>24.3%</td>
</tr>
<tr>
<td>ACR 50</td>
<td>85.3%*</td>
<td>10.8%</td>
</tr>
<tr>
<td>ACR 70</td>
<td>70.7%*</td>
<td>8.1%</td>
</tr>
<tr>
<td>ACR 90</td>
<td>37.3%*</td>
<td>5.4%</td>
</tr>
</tbody>
</table>

* p<0.0001, tocilizumab vs. placebo

### Systemic Features

In those patients treated with tocilizumab, 85% who had fever due to sJIA at baseline were free of fever (no temperature
recording ≥ 37.5°C in the preceding 14 days) at week 12 versus only 21% of placebo patients (p<0.0001) and 64% of tocilizumab treated patients with rash characteristic of sJIA at baseline were free of rash at week 12 versus 11% of placebo patients (p=0.0008).

There was a highly statistically significant reduction in pain for tocilizumab treated patients at week 12 in comparison to placebo patients. The adjusted mean change in the pain VAS after 12 weeks of tocilizumab treatment was a reduction of 41 points on a scale of 0 -100 compared to a reduction of 1 for placebo patients (p<0.0001). The responses for systemic features are maintained in the open label extension.

**Corticosteroid Tapering**

Of the 31 placebo and 70 tocilizumab patients receiving oral corticosteroids at baseline, 8 placebo and 48 tocilizumab patients achieved a JIA ACR70 response at week 6 or 8 enabling corticosteroid dose reduction. Seventeen (24%) tocilizumab patients versus 1 (3%) placebo patient were able to reduce the dose of corticosteroid by at least 20% without experiencing a subsequent JIA ACR30 flare or occurrence of systemic symptoms to week 12 (p=0.028). Reductions in corticosteroids continued, with 44 patients off oral corticosteroids, at week 44, while maintaining ACR responses.

**Quality of Life**

At week 12, the proportion of tocilizumab treated patients showing a minimally clinically important improvement in CHAQ-DI (defined as an individual total score decrease of ≥0.13) was significantly higher than in patients receiving placebo, 77% versus 19% (p<0.0001). Responses are maintained in the open label extension.

**Laboratory Parameters**

Fifty out of seventy five (67%) patients treated with tocilizumab had a haemoglobin below LLN at baseline. Forty (80%) of these patients with decreased haemoglobin had an increase in their haemoglobin to within the normal range at week 12, in comparison to only 2 out of 29 (7%) of placebo patients with haemoglobin below LLN at baseline (p<0.0001). Forty four (88%) tocilizumab patients with decreased haemoglobin at baseline had an increase in their haemoglobin by ≥10 g/L at week 6 versus 1 (3%) placebo patient (p<0.0001).

The proportion of tocilizumab treated patients with thrombocytosis at baseline who had a normal platelet count at week 12 was significantly higher than in the placebo patients, 90% versus 4%, (p<0.0001).

A marked decrease in mean levels of acute phase reactants, CRP, ESR, and serum amyloid A occurred rapidly after tocilizumab administration.

A Phase I, multi-centre, open-label, single arm study (NP25737) to evaluate the PK, safety and exploratory PD and efficacy of tocilizumab over 12 weeks in paediatric sJIA patients (N=11) under 2 years of age was conducted. Patients (treated with stable background therapy of corticosteroids, MTX, or nonsteroidal anti-inflammatory drugs) received intravenous tocilizumab 12 mg/kg every two weeks. Patients who completed the 12-week period could continue to the optional extension period (a total of 52-weeks or until the age of 2 years, whichever was longer).

The primary PK endpoints (Cmax, Cmin and AUC2weeks) of TCZ at steady-state in this study are within the ranges of these parameters observed in paediatric patients aged 2 to 17 years in Study WA18221.

The types of AEs observed during the 12-week evaluation period of Study NP25737 were consistent with the safety profile observed in the pivotal Phase III study (WA18221). Of the 11 patients aged under 2 years, three experienced serious hypersensitivity reactions, and three developed treatment induced antitocilizumab antibodies after the event. However, due to the small sample size, the low number of events and confounding factors, conclusions could not be drawn.

Exploratory efficacy results showed that tocilizumab improved the median JADAS-71 score over the course of the study for all patients. The observed PD responses in sIL6R, CRP, and ESR were also consistent with the pivotal Phase III study. A 52-week, open-label, multi-centre, PK/PD and safety study (WA28118) was conducted in paediatric patients with sJIA, aged 1 to 17 years, to determine the appropriate SC dose of TCZ that achieved comparable PK/PD and safety profiles to
 Eligible patients received TCZ dosed according to body weight (BW), with patients weighing 30 kg (n = 26) dosed with 162 mg of TCZ every week (QW) and patients weighing below 30 kg (n = 25) dosed with 162 mg of TCZ every 10 days (Q10D; n=8) or every 2 weeks (Q2W; n=17) for 52 weeks. Of these 51 patients, 26 (51%) were naive to TCZ and 25 (49%) had been receiving IV TCZ and switched to SC TCZ at baseline.

### 3.2 Pharmacokinetics Properties

PK of tocilizumab is characterized by nonlinear elimination which is a combination of linear clearance and Michaelis-Menten elimination. The nonlinear part of Tocilizumab elimination leads to an increase in exposure that is more than dose-proportional. The pharmacokinetic parameters of tocilizumab do not change with time. Due to the dependence of total clearance on tocilizumab serum concentrations, the half-life of tocilizumab is also concentration-dependent and varies depending on the serum concentration level. Population pharmacokinetic analyses in any patient population tested so far indicate no relationship between apparent clearance and the presence of anti-drug antibodies.

**Rheumatoid Arthritis**

The pharmacokinetics in healthy subjects and RA patients suggest that PK is similar between the two populations. The table below shows model predicted secondary PK parameters at each of the four approved dose regimens. The population PK (popPK) model was developed from an analysis dataset composed of an IV dataset of 1793 patients from studies WA17822, WA17824, WA18062 and WA18063 and IV and SC dataset of 1759 patients from studies WA22762 and NA25220. Cmean is included in the table since for dosing regimens with different inter-dose interval, the mean concentration over the dosing period characterizes the comparative exposure better than AUCτ.

<table>
<thead>
<tr>
<th>TCZ PK Parameter</th>
<th>IV</th>
<th>SC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4 mg/kg Q4W</td>
<td>8 mg/kg Q4W</td>
</tr>
<tr>
<td>Cmax (mcg/mL)</td>
<td>83.8 ± 23.1</td>
<td>182 ± 50.4</td>
</tr>
<tr>
<td>Ctrough (mcg/mL)</td>
<td>0.5 ± 1.5</td>
<td>15.9 ± 13.1</td>
</tr>
<tr>
<td>Cmean (mcg/mL)</td>
<td>17.8 ± 6.1</td>
<td>56.6 ± 19.3</td>
</tr>
<tr>
<td>Accumulation Cmax</td>
<td>1.01</td>
<td>1.09</td>
</tr>
<tr>
<td>Accumulation Ctrough</td>
<td>2.62</td>
<td>2.47</td>
</tr>
<tr>
<td>Accumulation Cmean or AUCτ *</td>
<td>1.09</td>
<td>1.32</td>
</tr>
</tbody>
</table>

*τ = 4 weeks for IV regimens, 2 week or 1 week for the two SC regimens, respectively

At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates. While after IV administration maximum concentration (Cmax) increased dose-proportionally between doses of 4 and 8 mg/kg IV every 4 weeks, a greater than dose-proportional increase was observed in the average concentration (Cmean)
at steady-state, $C_{\text{mean}}$ and $C_{\text{trough}}$ were 3.2 and 32 fold higher at 8 mg/kg as compared to 4 mg/kg, respectively. Exposures after the 162 mg SC QW regimen were greater by 4.6 ($C_{\text{mean}}$) to 7.5 fold ($C_{\text{trough}}$) compared to the 162 SC Q2W regimen. The accumulation ratios for AUC and $C_{\text{max}}$ after multiple doses of 4 and 8 mg/kg Q4W are low, while the accumulation ratios are higher for $C_{\text{trough}}$ (2.62 and 2.47). Accumulation ratios after multiple doses of either SC regimen were higher than after IV regimen with the highest ratios for $C_{\text{trough}}$ (6.02 and 6.30). The higher accumulation for $C_{\text{trough}}$ was expected based on the nonlinear clearance contribution at lower concentrations. For $C_{\text{max}}$, more than 90% of the steady-state was reached after the 1st IV infusion, and after the 12th SC and the 5th SC injection in QW and Q2W regimens respectively. For $AUC_t$ and $C_{\text{mean}}$, 90% of the steady-state was reached after the 1st and 3rd infusion for the 4 mg/kg and 8 mg/kg IV, respectively, and after the 6th and 12th injections for the 162 mg SC Q2W and QW regimens respectively. For $C_{\text{trough}}$, approximately 90% of the steady-state was reached after the 4th IV infusion, the 6th and 12th injections for the respective SC regimens. Population PK analysis identified body weight as a significant covariate impacting pharmacokinetics of tocilizumab. When given IV on a mg/kg basis, individuals with body weight ≥ 100 kg are predicted to have mean steady-state exposures higher than mean values for the patient population. Therefore, tocilizumab doses exceeding 800 mg per infusion are not recommended in patients ≥ 100 kg (see section 2.2 Dosage and Administration). Due to the flat dosing employed for SC administration of tocilizumab, no modifications are necessary by this dosing route. **Polyarticular juvenile idiopathic arthritis (pJIA)**

The pharmacokinetics of tocilizumab in pJIA patients was characterized by a population pharmacokinetic analysis which included 237 patients who were treated with 8 mg/kg IV every 4 weeks (patients weighing ≥ 30 kg), 10 mg/kg IV every 4 weeks (patients weighing below 30 kg),

<table>
<thead>
<tr>
<th>TCZ PK Parameter</th>
<th>IV</th>
<th>SC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>8 mg/kg</td>
<td>10 mg/kg Q4W</td>
</tr>
<tr>
<td></td>
<td>Q4W ≥ 30 kg</td>
<td>below 30 kg</td>
</tr>
<tr>
<td>$C_{\text{max}}$</td>
<td>183 ± 42.3</td>
<td>168 ± 24.8</td>
</tr>
<tr>
<td>$C_{\text{trough}}$</td>
<td>6.55 ± 7.93</td>
<td>1.47 ± 2.44</td>
</tr>
<tr>
<td>$C_{\text{mean}}$</td>
<td>42.2 ± 13.4</td>
<td>31.6 ± 7.84</td>
</tr>
<tr>
<td>Accumulation $C_{\text{max}}$</td>
<td>1.04</td>
<td>1.01</td>
</tr>
<tr>
<td>Accumulation $C_{\text{trough}}$</td>
<td>2.22</td>
<td>1.43</td>
</tr>
<tr>
<td>Accumulation $C_{\text{mean}}$ or $AUC_t$</td>
<td>1.16</td>
<td>1.05</td>
</tr>
</tbody>
</table>

*τ = 4 weeks for IV regimens, 2 week or 3 week for the two SC regimens, respectively

Table 11: Predicted mean ± SD PK parameters at steady-state after IV or SC dosing in pJIA

After IV dosing, approximately 90% of the steady-state was reached by Week 12 for the 10 mg/kg (BW < 30 kg), and by Week 16 for the 8 mg/kg (BW ≥ 30 kg) dose.
Systemic juvenile idiopathic arthritis (sJIA)
The pharmacokinetics of tocilizumab in sJIA patients was characterized by a population pharmacokinetic analysis which included 140 patients who were treated with 8 mg/kg IV every 2 weeks (patients weighing ≥ 30 kg), 12 mg/kg IV every 2 weeks (patients weighing below 30 kg).

Table 12: Predicted mean ± SD PK parameters at steady-state after IV or SC dosing in sJIA

<table>
<thead>
<tr>
<th>TCZ PK Parameter</th>
<th>IV</th>
<th>SC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>8 mg/kg Q2W</td>
<td>12 mg/kg Q2W below 30 kg</td>
</tr>
<tr>
<td>(C_{\text{max}}) (µg/mL)</td>
<td>256 ± 60.8</td>
<td>274 ± 63.8</td>
</tr>
<tr>
<td>(C_{\text{trough}}) (µg/mL)</td>
<td>69.7 ± 29.1</td>
<td>68.4 ± 30.0</td>
</tr>
<tr>
<td>(C_{\text{mean}}) (µg/mL)</td>
<td>119 ± 36.0</td>
<td>123 ± 36.0</td>
</tr>
<tr>
<td>Accumulation (C_{\text{max}})</td>
<td>1.42</td>
<td>1.37</td>
</tr>
<tr>
<td>Accumulation (C_{\text{trough}})</td>
<td>3.20</td>
<td>3.41</td>
</tr>
<tr>
<td>Accumulation (C_{\text{mean}}) or AUC(_\tau)*</td>
<td>2.01</td>
<td>1.95</td>
</tr>
</tbody>
</table>

*\(\tau = 2\) weeks for IV regimens, 1 week or 2 week for the two SC regimens, respectively

After IV dosing, approximately 90% of the steady-state was reached by Week 8 for both the 12 mg/kg and 8 mg/kg Q2W regimens. After SC dosing, approximately 90% of the steady-state was reached by Week 12 for both the 162 mg QW and Q2W regimens.

The pharmacokinetics of tocilizumab were similar in paediatric patients under 2 years compared to patients over 2 years of age with a body weight below 30 kg from a regimen of 12 mg/kg IV tocilizumab given every 2 weeks.

3.2.1 Absorption
No text.

3.2.2 Distribution
Following IV dosing, tocilizumab undergoes biphasic elimination from the circulation. In rheumatoid arthritis patients the central volume of distribution was 3.5 L, the peripheral volume of distribution was 2.9 L resulting in a volume of distribution at steady state of 6.4 L.
In paediatric patients with pJIA, the central volume of distribution was 1.98 L, the peripheral volume of distribution was 2.1 L, resulting in a volume of distribution at steady state of 4.08 L.
In paediatric patients with sJIA, the central volume of distribution was 1.87 L, the peripheral volume of distribution was 2.14 L resulting in a volume of distribution at steady state of 4.01 L.

3.2.3 Metabolism
No text.

3.2.4 Elimination
The total clearance of tocilizumab was concentration-dependent and is the sum of the linear clearance and the nonlinear
clearance. The linear clearance was estimated as a parameter in the population pharmacokinetic analysis and was 12.5 mL/h in RA patients, 5.8 mL/h in paediatric patients with polyarticular juvenile idiopathic arthritis and 5.7 mL/h in paediatric patients with systemic juvenile idiopathic arthritis. The concentration-dependent nonlinear clearance plays a major role at low tocilizumab concentrations. Once the nonlinear clearance pathway is saturated, at higher tocilizumab concentrations, clearance is mainly determined by the linear clearance. Due to dependence of total clearance on tocilizumab serum concentrations, t1/2 of tocilizumab is also concentration dependent and can only be calculated at a given serum concentration level.

In RA patients, for intravenous administration, the concentration-dependent apparent t1/2 is up to 11 days for 4 mg/kg and 13 days for 8 mg/kg every 4 weeks in patients with RA at steady-state. At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal t1/2 of approximately 21.5 days was derived from the population parameter estimates.

In children with pJIA, the effective t1/2 of IV tocilizumab is up to 17 days for the two body weight categories (8 mg/kg for body weight ≥ 30 kg or 10 mg/kg for body weight below 30 kg) during a dosing interval at steady state.

In children with sJIA, the effective t1/2 of IV tocilizumab is up to 16 days for both the 12 mg/kg and 8 mg/kg Q2W regimens during a dosing interval at steady-state.

3.2.5. Pharmacokinetics in Special Populations

Hepatic Impairment
No formal study of the effect of hepatic impairment on the pharmacokinetics of tocilizumab was conducted.

Renal Impairment:
No formal study of the effect of renal impairment on the pharmacokinetics of tocilizumab has been conducted.
Most of the patients in the RA population pharmacokinetic analysis had normal renal function or mild renal impairment.
Mild renal impairment (estimated creatinine clearance based on Cockcroft-Gault formula) did not impact the pharmacokinetics of tocilizumab.
Approximately one-third of the patients in the study WA28119 had moderate renal impairment at baseline (estimated creatinine clearance of 30-59 mL/min). No impact on tocilizumab exposure was noted in these patients.
No dose adjustment is required in patients with mild or moderate renal impairment.

Other special populations
Population pharmacokinetic analyses in adult RA patients showed that age, sex and race did not affect pharmacokinetics of tocilizumab. No dose adjustment is necessary for these demographic factors.

3.3 Non-clinical Safety

3.3.1 Carcinogenicity
A carcinogenicity study of tocilizumab has not been conducted. Available preclinical data, showed the contribution of the pleiotropic cytokine IL-6 to malignant progression and apoptosis resistance of various cancer types. These data do not suggest a relevant risk for cancer initiation and progression under therapy with tocilizumab. Accordingly, proliferate lesions have not been observed in a chronic cynomolgus monkey 6-month toxicity study nor were they described in IL-6 knock-out mice under chronic IL-6 depletion.

3.3.2 Genotoxicity
Standard genotoxicity studies with tocilizumab in both prokaryotic and eukaryotic cells were all negative.

3.3.3 Impairment of Fertility
Non-clinical data do not suggest an effect on fertility under treatment with an analogue of tocilizumab. Effects on endocrine active organs or on organs of the reproductive system were not seen in a chronic cynomolgus monkey toxicity study, nor was the reproductive performance affected in IL-6 deficient male and female mice.

3.3.4 Reproductive toxicity
When tocilizumab was administered intravenously to cynomolgus monkeys during early gestation, no direct or indirect harmful effects on pregnancy or embryo-foetal development were observed.

3.3.5 Other
In an embryo-foetal toxicity study conducted in cynomolgus monkeys a slight increase of abortion/embryo-foetal death was observed with high systemic cumulative exposure (above 100 times human exposure) in the 50 mg/kg/day high-dose group compared to placebo and other low-dose groups. The abortion incidence was within the historical background for the cynomolgus monkey in captivity and the individual cases of abortions/embryo-foetal death did not show any consistent relationship to dosing or duration of dosing with tocilizumab. Although IL-6 does not seem to be a critical cytokine for either foetal growth or the immunological control of the maternal/foetal interface, a relation of this finding to tocilizumab cannot be excluded.

Transfer of a murine analogue of tocilizumab into the milk of lactating mice has been observed. Treatment with a murine analogue did not exert toxicity in juvenile mice. In particular, there was no impairment of skeletal growth, immune function and sexual maturation.

The non-clinical safety profile of tocilizumab in the cynomolgus monkey does not suggest a difference between IV and SC routes of administration.

4. Pharmaceutical Particulars

4.1 Storage

Intravenous tocilizumab:
This medicine should not be used after the expiry date (Expiry date) shown on the pack.
For vials: Store between 2ºC – 8ºC, do not freeze. Keep the container in the outer carton in order to protect from light.
For prepared infusion solution: The prepared infusion solution of tocilizumab is physically and chemically stable in 0.9% w/v sodium chloride solution at 30ºC for 24 hours.
From a microbiological point of view, the prepared infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2ºC – 8ºC, unless dilution has taken place in controlled and validated aseptic conditions.

4.2 Special Instructions for Use, Handling and Disposal

Intravenous Tocilizumab:
Parenteral medications should be inspected visually for particulate matter or discoloration prior to administration. Only solutions which are clear to opalescent, colourless to pale yellow and free of visible particles must be infused.

Rheumatoid Arthritis:
From a 100 mL infusion bag, withdraw a volume of 0.9% Sodium Chloride solution equal to the volume of the tocilizumab solution required for the patient’s dose. Withdraw the required amount of tocilizumab (0.4 mL/kg) under aseptic conditions and dilute to a calculated tocilizumab concentration in a 100 mL infusion bag containing sterile, non-pyrogenic 0.9% Sodium Chloride solution. To mix the solution, gently invert the bag to avoid foaming.

pJIA and sJIA Patients ≥ 30 kg:
From a 100 mL infusion bag, withdraw a volume of 0.9% Sodium Chloride solution equal to the volume of the tocilizumab solution required for the patient’s dose. Withdraw the required amount of tocilizumab (0.4 mL/kg) under aseptic conditions and dilute to a calculated tocilizumab concentration in a 100 mL infusion bag containing sterile, non-pyrogenic 0.9% Sodium Chloride solution. To mix the solution, gently invert the bag to avoid foaming.

pJIA Patients below 30 kg:
From a 50 mL infusion bag, withdraw a volume of 0.9% Sodium Chloride solution equal to 0.5 mL/kg of the patient’s body
weight and discard. This volume should be replaced in the saline bag with an equal volume of tocilizumab under aseptic conditions. To mix the solution, gently invert the bag to avoid foaming.

**sJIA Patients below 30 kg:**
From a 50 mL infusion bag, withdraw a volume of 0.9% Sodium Chloride solution equal to 0.6 mL/kg of the patient’s body weight and discard. This volume should be replaced in the saline bag with an equal volume of tocilizumab under aseptic conditions. To mix the solution, gently invert the bag to avoid foaming.

### 4.3 Shelf Life

**Unopened vial:** 30 months when stored at recommended storage conditions.

**Disposal of unused/expired medicines**
The release of pharmaceuticals in the environment should be minimized. Medicines should not be disposed of via wastewater, and disposal through household waste should be avoided. Use established ‘collection systems’ if available in your location.

### 4.4 Pack Sizes (vials for IV infusion use only)

<table>
<thead>
<tr>
<th>Presentations</th>
<th>Pack sizes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vials 80 mg/4 ml</td>
<td>1</td>
</tr>
<tr>
<td>Vials 200 mg/10 ml</td>
<td>1</td>
</tr>
<tr>
<td>Vials 400 mg/20 ml</td>
<td>1</td>
</tr>
</tbody>
</table>

Keep out of reach of children

Current at April 2019, Version 9.0

Manufactured by: F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070, Basel, Switzerland at Chugai Pharma Manufacturing Co., Ltd., 16-3, Kiyohara Kogyodanchi, Utsunomiya-City, Tochigi 321-3231, Japan

Imported by: Roche Products (India) Pvt. Ltd., Plot No.13-A, Paper Box House, Survey No.78, Hissa No.1, CTS No.46/15, Mahakali Road, Andheri (East), Mumbai- 400093 India

Distributed and Marketed by:

Cipla Ltd.,
Cipla House, Peninsula Business Park,
Ganpatrao Kadam Marg,
Lower Parel, Mumbai 400 013, India

---

**Actemra® Injection**

Source URL: https://ciplamed.com/content/actemra-injection